柠檬酸盐功能化的二氧化锰在肝纤维化纳米治疗中的口服给药应用。
Citrate functionalized MnO in nanotherapy of hepatic fibrosis by oral administration.
作者信息
Adhikari Aniruddha, Polley Nabarun, Darbar Soumendra, Bagchi Damayanti, Pal Samir Kumar
机构信息
Department of Chemical, Biological & Macromolecular Sciences, S. N. Bose National Centre for Basic Sciences, Block JD, Sector III, Salt Lake, Kolkata 700106, India; Department of Chemical, Biological & Macromolecular Sciences, S. N. Bose National Centre for Basic Sciences, Block JD, Sector III, Salt Lake, Kolkata 700106, India.
Research & Development Division, Dey's Medical Stores (Mfg.) Ltd., 62, Bondel Road, Ballygunge, Kolkata 700019, India; Research & Development Division, Dey's Medical Stores (Mfg.) Ltd., 62, Bondel Road, Ballygunge, Kolkata 700019, India.
出版信息
Future Sci OA. 2016 Oct 6;2(4):FSO146. doi: 10.4155/fsoa-2016-0029. eCollection 2016 Dec.
AIM
To test the potential of orally administered citrate functionalized MnO nanoparticles (C-MnO NPs) as a therapeutic agent against hepatic fibrosis and associated chronic liver diseases.
MATERIALS & METHODS: C-MnO NPs were synthesized and the pH dependent antioxidant mechanism was characterized by studies. CCl intoxicated mice were orally treated with C-MnO NPs to test its antioxidant and antifibrotic ability.
RESULTS
We demonstrated ultrahigh efficacy of the C-MnO NPs in treatment of chronic liver diseases such as hepatic fibrosis and cirrhosis in mice compared with conventional medicine silymarin without any toxicological implications.
CONCLUSION
These findings may pave the way for practical clinical use of the NPs as safe medication of chronic liver diseases associated with fibrosis and cirrhosis in human subjects.
目的
测试口服柠檬酸盐功能化的二氧化锰纳米颗粒（C-MnO NPs）作为抗肝纤维化及相关慢性肝病治疗剂的潜力。
材料与方法
合成C-MnO NPs，并通过研究表征其pH依赖性抗氧化机制。用CCl诱导小鼠中毒，然后口服C-MnO NPs以测试其抗氧化和抗纤维化能力。
结果
与传统药物水飞蓟素相比，我们证明了C-MnO NPs在治疗小鼠慢性肝病（如肝纤维化和肝硬化）方面具有超高疗效，且无任何毒理学影响。
结论
这些发现可能为将该纳米颗粒实际临床应用于人类受试者中与纤维化和肝硬化相关的慢性肝病的安全药物铺平道路。
Zotero 插件